• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121
Citation: DING Jinxi, LIU Weijing, LI Wei, LIU Yangyang, BAI Gengliang. Analysis of orphan drug accessibility and marketing authorization system in China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 111-117. DOI: 10.11665/j.issn.1000-5048.20140121
shu

Analysis of orphan drug accessibility and marketing authorization system in China

More Information
    Graphical Abstract
    • Abstract
  • According to the status-quo of orphan drug access in China, this paper constructedan index evaluation system so as to provide referable foundationfor establishing and improving orphan drug authorization system. Study results indicated that the less-improved orphan drug marketing authorization system, poorer orphan drug availability, supply capacity and affordability compared with developed countries and regions severely affected patients′ timely medication and hindered orphan drug industry development. With reference to foreign countries, it is urgent to improve orphan drugs marketing authorization system for the purpose of encouraging orphan drug R&D and improving the health benefits of patients.
    • FullText(HTML)
    • References (28)
  • [1]
    U.S.Food and Drug Administration(FDA).Rare diseases take spotlight in annual event[EB/OL].(2011-02-24)[2012-12-22].http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm244408.htm.
    [2]
    Gong SW,Zhang M.Thinking on the definitions of rare disease and orphan drugs in China[J].Chin J New Drugs(中国新药杂志),2006(15):1 225-1 229.
    [3]
    Tao Y.The current situation of orphan drug regulation in the United States[J].Chin Pharm J(中国药学杂志),2001,36(9):634-636.
    [4]
    Jiang H.Review and reference on the USA drug market access system[J].Guangxi Soc Sci(广西社会科学),2013(2):89-93.
    [5]
    Zhu JP.Exploration of ancient Chinese on the relation of geographical environment tohuman diseases[J].China J Tradit Chin Med Pharm(中华中医药杂志),2011,26(12):2 791-2 794.
    [6]
    Xin ZJ,Wang ZS,Chen ZJ.Studying the status of orphan drugs in China and its countermeasures[J].Chin Health Serv Manage(中国卫生事业管理),2011(5):349-351.
    [7]
    Li HT.Analys is on the accessibility of drugs in China[J].Chin Health Serv Manage(中国卫生事业管理),2009(9):612-614.
    [8]
    Ding JX, Li XT, Zhao Y. The unify operation pattern of drug reimbursement list under the policy of new medical reform-based on the empirical analyses of the drug reimbursement list of new cooperative medical system[J].Chin Pharm Aff(中国药事),2011,25(10):962-968.
    [9]
    Liu LQ.Research on strategies of essential medicines availability in community health service facilities(促进社区卫生服务机构基本药物可获得性策略研究)[D].Wuhan:Huazhong University of Science and Technology,2009.
    [10]
    U.S.Food and drug administration.search orphan drug designations and approvals[EB/OL].(2012-12-02)[2013-01-03].http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm.
    [11]
    List of medicinal products for rare diseases in Europe [EB/OL].(2013-10-01)[2013-12-20].http://www.orpha.net/orphancome/cahriers/docs/GB/list_of_orphan_drugs_in_europe.pdf.
    [12]
    Ministry of Health,Labour and Welfare.Rare disease medicine formulated product catalogue[EB/OL].[2008-09-05](2013-01-03).http://www.mhlw.go.jp/english/index.html.
    [13]
    Korea food and drug administration[EB/OL].[2012-08-30](2012-12-29).http://www.mfds.go.kr/index.do.
    [14]
    China Food and Drug Administration. State Food and Drug Administration issued ″special approval of new drug registration regulations″[EB/OL].[2009-01-09](2013-01-01).http://www.sda.gov.cn/WS01/CL0051/35168.html.
    [15]
    Gao S.Do not let a rare disease ″rare″ drug[N].Health News(健康报),2010-06-19(5).
    [16]
    Gong SW. Management strategies of improving orphan drugs access in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Wuhan:Huazhong University of Science and Technology,2008.
    [17]
    Sun GJ.Discussion about market concentration ratio of pharmaceutical industry in China[J].Chin Pharm(中国药房),2004,15(4):588-590.
    [18]
    Rare Disease Relief Public Fund.China rare disease network[EB/OL].(2010-01-01)[2012-12-26].http://www.chinararedisease.cn/5-7.html.
    [19]
    Global concern on the orphan drug development[N].China High-Tech Industry Health(中国高新技术产业导报).2002-07-03(5).
    [20]
    Zhang L.Orphan drug development prospect analysis[N].Med Econ News(医药经济报),2002-06-24(2).
    [21]
    Gong SW,Xu Y,Zhang L.Study on evaluation indicator system of drug accessibility[J].Chin Health Econ(中国卫生经济),2011,30(5):72-74.
    [22]
    Zhang RW,Hu SL.A comparative study of international price for pharmaceuticals medicine price[J].Chin Health Econ(中国卫生经济),2001,20(2): 26-28.
    [23]
    Ding JX,Sun XD,Ji N,et al.Availability evaluation and safeguard legal system research for orphan drugs in US and China[J].Chin Pharm J(中国药学杂志),2011(14):1 129-1 132.
    [24]
    Yang L,Hu SL,Gong YC.International experience of pharmacoeconomic evaluation in health decision-making[J].Chin Pharm(中国药房),2004(6):347-351.
    [25]
    Hu JJ,Luo AQ,Xu P,et al.Analysis of international medical insurance status orphan drugs[R]. 2012年中国药学会药事管理专业委员会年会论文集(上册).Beijing:2012-08-11.
    [26]
    Lin YH,Wu XM.Design of orphan drug industrial policy[J].Modern Management Sci(现代管理科学),2012(5):9-11.
    [27]
    Li MY.Provide the necessary protection for rare diseases medical[N].People′s Political Consultative Daily(人民政协报),2010-03-10:(D02).
    [28]
    Zhong X.Rare diseases is likely into health insurance directory next year[J].China Health Insurance(中国医疗保险),2012(8):71.
    • Related Articles

  • Related Articles

    [1]ZHAO Yifei, GENG Xin, XU Lihua, OU Ting, ZHANG Ning. Considerations on the chemistry, manufacture and control requirements for conditional marketing authorization drugs in China[J]. Journal of China Pharmaceutical University, 2021, 52(5): 636-642. DOI: 10.11665/j.issn.1000-5048.20210518
    [2]YUAN Ni, TIAN Tingting, ZHANG Haijun, WANG Yong. Major routes for orphan drugs to be incorporated into the reimbursement system of UK and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2019, 50(1): 113-119. DOI: 10.11665/j.issn.1000-5048.20190116
    [3]WANG Ennan, CHEN Yi, CHU Shuzhen. Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China[J]. Journal of China Pharmaceutical University, 2017, 48(6): 745-750. DOI: 10.11665/j.issn.1000-5048.20170618
    [4]DING Jinxi, LIU Yangyang, YAN Jianzhou. Negative effects of drug data protection system on drug availability — an empirical analysis of America lamotrigine case[J]. Journal of China Pharmaceutical University, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
    [5]SHAO Rong, YIN Tianhong. Charging system in US PDUFA with reference to speeding up drug evaluation process of China[J]. Journal of China Pharmaceutical University, 2014, 45(3): 281-285. DOI: 10.11665/j.issn.1000-5048.20140305
    [6]CHU Shuzhen, LI Weixia. Incentive measures for orphan drug R&D in several Asian countries and regions and the enlightenment to China[J]. Journal of China Pharmaceutical University, 2014, 45(1): 125-128. DOI: 10.11665/j.issn.1000-5048.20140123
    [7]DING Zhichen, WEI Guan, DING Jinxi. Orphan drug regime in Japan and enlightenment on China:based on evaluation of orphan drug access in Japan[J]. Journal of China Pharmaceutical University, 2014, 45(1): 118-124. DOI: 10.11665/j.issn.1000-5048.20140122
    [8]SHEN Yu. Perspectives on current protection system of traditional Chinese medicine[J]. Journal of China Pharmaceutical University, 2011, 42(2): 189-192.
    [9]WU Zheng, ZHENG Feng, DING Li. Development of in-vitro evaluation methods to access membrane permeability of drugs[J]. Journal of China Pharmaceutical University, 2011, 42(1): 16-21.
    [10]System Separation of Cyclosporin A Triple Therapeutic Drugs by Micellar Electrokinetic Capillary Chromatography and Evaluation of Optimal Method Ruggedness[J]. Journal of China Pharmaceutical University, 1999, (5): 373-376.

Catalog

    Get Citation
    PDF
    XML
    Article views (1438) PDF downloads (3231) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：415103

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return